At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 20 target
Drug / intervention
AlloRxbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT05152290Phase 1RecruitingMonitorUpdated 14mo ago · Completion was 5mo agoSlow Enrollment
Long Recruiting
Monitor
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Spinal Cord Injury
The Foundation for Orthopaedics and Regenerative Medicine·interventional·Posted Dec 9, 2021·Updated Apr 8, 2025
In Brief
A Phase 1 clinical trial evaluating AlloRx for Spinal Cord Injuries. Currently recruiting, targeting 20 participants across 2 sites in 2 countries.
Signals
Enrolling slower than its timeline implies
Detailed Summary
This trial will study the safety and efficacy of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Spinal Cord Injury.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpinal Cord Injuries
CountriesAntigua and Barbuda, Greece
Collaborators--
Timeline
Phase 1RecruitingOverdue
20222023202420252026
First PostedDec 2021
Enrollment StartJul 2022
Primary CompletionJan 2026
TodayJul 2026
First PostedDec 9, 2021
Enrollment StartJul 6, 2022
Primary CompletionJan 1, 2026
TodayJul 1, 2026
Enrollment to primary: 3.5 yearsPosted 4.6 years ago
Interventions
AlloRxbiological
cultured allogeneic adult umbilical cord derived mesenchymal stem cells